Published on 21/12/2025
FDA Type A, B, and C Meetings in U.S. Clinical Development Programs
Introduction
Regulatory meetings with the U.S. Food and Drug Administration (FDA) are a cornerstone of clinical development, ensuring clarity, alignment, and efficiency across all phases of drug and biologic programs. The FDA provides sponsors with opportunities to engage through formal Type A, B, and C meetings, each designed to address specific regulatory needs. These interactions shape trial design, resolve disputes, clarify regulatory expectations, and accelerate development timelines. This article explores the regulatory framework, types of FDA meetings, case studies, and best practices for sponsors planning U.S. clinical trials.
Background / Regulatory Framework
Meeting Types Defined
FDA classifies sponsor-requested meetings into three categories:
- Type A Meetings: Urgent meetings to resolve stalled programs or critical clinical holds.
- Type B Meetings: Key development milestone meetings such as Pre-IND, End-of-Phase 2, and Pre-NDA/BLA meetings.
- Type C Meetings: Any other meetings that address issues not fitting into Type A or B, often strategic or clarifying discussions.
Guidance and Timelines
The FDA formalized meeting processes under the PDUFA framework. Timelines are defined: 30 days for Type A, 60 days for Type B, and 75 days for Type
Case Example—Type A Resolution
A sponsor received a clinical hold due to inadequate preclinical toxicology data. Through a Type A meeting, the sponsor and FDA agreed on additional studies, enabling trial resumption within weeks.
Core Clinical Trial Insights
1) Type A Meetings
Reserved for critical path issues such as clinical holds, dispute resolution, or stalled development programs. They are high-priority and scheduled quickly to resolve urgent problems.
2) Type B Meetings
These occur at pivotal development milestones. Examples include Pre-IND, End-of-Phase 2, and Pre-NDA/BLA meetings. FDA uses these sessions to align on study design, endpoints, safety databases, and submission requirements.
3) Type C Meetings
These meetings provide flexibility to discuss emerging issues such as novel trial designs, use of digital endpoints, or real-world evidence integration. They are essential for programs involving innovative technologies.
4) Meeting Packages
FDA requires sponsors to submit briefing documents containing background, specific questions, and supporting data. Well-prepared packages drive meaningful discussions and regulatory clarity.
5) Communication Methods
Meetings may occur face-to-face, via teleconference, or through written responses. FDA increasingly accommodates virtual formats to improve accessibility and efficiency.
6) Impact on Development Timelines
Effective meetings accelerate clinical development, resolve uncertainties early, and reduce regulatory risk. Poorly prepared meetings can delay programs and erode FDA confidence.
7) Role of FDA Review Divisions
Different review divisions within the FDA coordinate meetings based on therapeutic area expertise. Sponsors must understand division priorities and align expectations accordingly.
8) Integration with Global Programs
FDA meetings often inform global development strategies by aligning with EMA scientific advice or PMDA consultations, ensuring harmonized clinical trial planning.
9) Common Pitfalls
Incomplete meeting packages, vague questions, and lack of preparation are common pitfalls. Sponsors must approach meetings strategically to maximize value.
10) Case Studies of Successful Meetings
Examples include oncology programs receiving accelerated approval after clear endpoint alignment in Type B meetings, or rare disease therapies advancing due to FDA’s guidance in Type C discussions.
Best Practices & Preventive Measures
Sponsors should: (1) submit detailed meeting packages; (2) craft focused regulatory questions; (3) prepare multidisciplinary teams; (4) align internal decision-making before meetings; (5) document FDA responses carefully; (6) engage regulatory experts; (7) consider mock rehearsals; (8) maintain respectful and collaborative interactions; (9) follow up promptly with meeting minutes; and (10) integrate FDA advice into global strategy.
Scientific & Regulatory Evidence
References include FDA’s Guidance for Industry “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products” (2017), PDUFA VI performance goals, and relevant CFR sections. These documents define expectations for meeting requests and conduct.
Special Considerations
Rare disease and oncology programs benefit disproportionately from FDA meetings due to complex endpoints and accelerated approval pathways. Sponsors must prepare for nuanced discussions in these areas.
When Sponsors Should Seek Regulatory Advice
Sponsors should request meetings early during protocol development, at milestone transitions, and when novel trial designs or endpoints are proposed. Proactive engagement prevents costly delays and regulatory misalignment.
Case Studies
Case Study 1: Type B Pre-IND Success
A biotech company received FDA alignment on biomarkers during a Pre-IND meeting, accelerating trial initiation and ensuring regulatory acceptance.
Case Study 2: Type C Digital Endpoint
A sponsor discussed the use of wearable-derived endpoints in a Type C meeting. FDA provided constructive guidance, paving the way for inclusion in pivotal trials.
Case Study 3: Type A Dispute Resolution
A sponsor facing protocol disagreements with FDA leveraged a Type A meeting to resolve issues quickly, preventing significant trial delays.
FAQs
1) What are FDA Type A, B, and C meetings?
Formal regulatory meetings categorized by urgency and purpose: Type A for urgent issues, Type B for key milestones, and Type C for all other topics.
2) How long does FDA take to schedule these meetings?
Type A: 30 days, Type B: 60 days, and Type C: 75 days from request submission.
3) What is required in a meeting package?
A detailed briefing document with background, data, and specific regulatory questions.
4) Are virtual FDA meetings allowed?
Yes, FDA increasingly accommodates teleconferences and virtual meetings, especially post-COVID-19.
5) Can FDA responses replace meetings?
Yes, in some cases FDA provides written responses in lieu of live meetings when appropriate.
6) How do FDA meetings impact trial timelines?
They clarify expectations, accelerate approvals, and reduce regulatory uncertainty when well executed.
7) How do FDA meetings align with global regulators?
FDA meetings often inform strategies aligned with EMA, PMDA, and other agencies for global program harmonization.
Conclusion & Call-to-Action
FDA Type A, B, and C meetings are vital tools for sponsors conducting clinical trials in the U.S. By engaging proactively, preparing thoroughly, and integrating FDA feedback into development strategies, sponsors can de-risk their programs and accelerate patient access to innovative therapies. Regulatory engagement is not just procedural—it is strategic.